PMS17 Cost-Effectiveness of denosumab vs. Brand or generic zoledronic acid in patients with prostate cancer in kazakhstan

Bektur, C.; Nurgozhin, T.

Басты бет
→
02.National Laboratory Astana
→
Center for Life Sciences
→
Laboratory of Epidemiology and Public Health
→
Элементті қарап шығу

Кеңейтілген іздеу

Система будет остановлена для регулярного обслуживания. Пожалуйста, сохраните рабочие данные и выйдите из системы.

PMS17 Cost-Effectiveness of denosumab vs. Brand or generic zoledronic acid in patients with prostate cancer in kazakhstan

Bektur, C.; Nurgozhin, T.

URI: https://www.sciencedirect.com/science/article/pii/S1098301514022633
http://nur.nu.edu.kz/handle/123456789/2874

Күні: 2014-11-01

Аннотация:

A phase III clinical trial demonstrated the advantage of denosumab over zoledronic acid(ZA) in delaying the first on-study and subsequent skeletal-related events(SREs) in patients with prostate cancer(PC). Recently, generic ZA became available. The purpose of this study was to examine the cost-effectiveness of denosumab vs. brand or generic ZA in the prevention of SREs in Kazakhstani patients with PC.

Толық ақпаратты көрсету